Alto Neuroscience IncNYSE:ANRO
- LAST PRICE14.1800
- TODAY'S CHANGE (%)0.0500 (0.3539%)
- Bid / Lots13.3000/ 3
- Ask / Lots15.9100/ 1
- Open / Previous Close13.9400 / 14.1300
- Day Range
- 52 Week Range
- Volume22,746
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANRO |
|---|---|---|
| 09:32 ET | 342 | 13.94 |
| 10:10 ET | 100 | 14.1 |
| 10:15 ET | 100 | 14.12 |
| 11:06 ET | 1000 | 14.12 |
| 11:11 ET | 100 | 14.075 |
| 11:51 ET | 1001 | 13.97 |
| 11:54 ET | 1431 | 14.03 |
| 12:05 ET | 300 | 14.05 |
| 12:07 ET | 100 | 14.045 |
| 12:50 ET | 1000 | 14.12 |
| 12:52 ET | 300 | 14.12 |
| 12:54 ET | 500 | 14.12 |
| 12:56 ET | 500 | 14.12 |
| 01:08 ET | 200 | 14.12 |
| 01:14 ET | 300 | 14.12 |
| 01:15 ET | 206 | 14.12 |
| 01:32 ET | 100 | 14.12 |
| 01:44 ET | 100 | 14.05 |
| 02:00 ET | 100 | 14.11 |
| 02:26 ET | 500 | 14.07 |
| 02:27 ET | 100 | 14.12 |
| 03:34 ET | 100 | 14.065 |
| 03:39 ET | 100 | 14.065 |
| 03:43 ET | 200 | 14.02 |
| 03:45 ET | 358 | 14.01 |
| 03:48 ET | 100 | 14.06 |
| 03:50 ET | 300 | 14.07 |
| 03:52 ET | 248 | 14.1 |
| 03:57 ET | 700 | 14.1 |
| 03:59 ET | 3669 | 14.18 |
Apr 23, 2024
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia, from 8:05AM ET on Tuesday Apr 23, 2024 by Dow Jones
8:05AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 3, 2024
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder, from 8:05AM ET on Wednesday Apr 03, 2024 by Dow Jones
8:05AM ET on Wednesday Apr 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alto Neuroscience Inc | 381.2M | -10.0x | --- |
Neurogene Inc | 385.1M | -1.0x | --- |
PepGen Inc | 386.0M | -3.6x | --- |
Biomea Fusion Inc | 386.9M | -3.1x | --- |
Replimune Group Inc | 394.1M | -2.0x | --- |
Lexicon Pharmaceuticals Inc | 389.1M | -2.0x | --- |
Company Information
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
Contact Information
- Headquarters
- 369 South San Antonio Rd.LOS ALTOS, CA, United States 94022
- Phone
- 773-255-5012
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Amit Etkin
- Chief Financial Officer
- Nicholas Smith
- Chief Medical Officer
- Adam Savitz
- Director
- Po Yu Chen
- Director
- Chris Dimitropoulos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $381.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 26.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.42 |
Book Value | $2.73 |
P/E Ratio | -10.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
